Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028
The chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area.
“Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period”
The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.
“Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period”
The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.
“Asia Pacific: The fastest-growing region chemiluminescence immunoassay market”
The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.
The break-up of the profile of primary participants in the chemiluminescence immunoassay market:
Research Coverage:
This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period”
The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.
“Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period”
The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.
“Asia Pacific: The fastest-growing region chemiluminescence immunoassay market”
The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.
The break-up of the profile of primary participants in the chemiluminescence immunoassay market:
- By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 – 31%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 37%, Europe - 28%, Asia Pacific - 20%, Rest of the World- 15%
Research Coverage:
This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (increasing incidences of chronic and infectious diseases, advances in improving the CLIA technologies, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, growing geriatric population, and shift towards personalized medicine), restraints (high cost of CLIA systems and reagents and cross-reactivity and interference), opportunities (high growth prospects in emerging countries and collaborations and partnerships), and challenges (unfavorable reimbursement scenario and lack of skilled professionals) influencing the growth of the chemiluminescence immunoassay market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the chemiluminescence immunoassay market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the chemiluminescence immunoassay market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the chemiluminescence immunoassay market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Seimens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A.(Italy), among others in the chemiluminescence immunoassay market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION
1.3.2 GEOGRAPHICAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 6 MARKET ESTIMATION FROM IVD MARKET
FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
FIGURE 9 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)
FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
4 PREMIUM INSIGHTS
4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW
FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022)
FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidences of chronic and infectious diseases globally
FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)
FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS)
5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years
5.2.1.3 Growth of biotechnology and biopharmaceutical industries
5.2.1.4 Rapid increase in geriatric population globally
FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.5 Shift toward personalized medicines and individualized treatment decisions
5.2.2 RESTRAINTS
5.2.2.1 High cost of chemiluminescence systems and reagents
5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference
5.2.3 OPPORTUNITIES
5.2.3.1 High growth prospects for players in emerging economies
5.2.3.2 Increasing number of collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems
5.2.4.2 Lack of skilled professionals and aging workforce
5.3 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
5.5.1 DEGREE OF COMPETITION
5.5.2 BARGAINING POWER OF SUPPLIERS
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 THREAT OF SUBSTITUTES
5.5.5 THREAT OF NEW ENTRANTS
5.6 KEY STAKEHOLDERS AND BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.6.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS
TABLE 4 KEY BUYING CRITERIA, BY END USER
5.7 REGULATORY LANDSCAPE
5.7.1 US
TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES
5.7.2 CANADA
FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.7.3 EUROPE
TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES
5.7.4 JAPAN
FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.5 CHINA
TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.6 INDIA
FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.7.7 INDONESIA
TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.7.8 RUSSIA
TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.7.9 SAUDI ARABIA
TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.10 MEXICO
FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.11 BRAZIL
FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.7.12 SOUTH KOREA
TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.13 MIDDLE EAST
5.7.14 AFRICA
5.8 TECHNOLOGY ANALYSIS
TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.9 TRADE ANALYSIS
5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
5.10 ECOSYSTEM MAPPING
FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.10.1 ROLE IN ECOSYSTEM
5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024
5.13 PRICING ANALYSIS
5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)
TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD
TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE
TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE
TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 CHEMILUMINESCENCE ENZYME
7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION)
7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY
7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY
7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
8.2 BLOOD
8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
8.3 URINE
8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET
TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.4 SALIVA
8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET
TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SAMPLE TYPES
TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET
TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET
TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 ONCOLOGY
9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.5 CARDIOLOGY
9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET
TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
9.7 BLOOD SCREENING
9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET
TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.8 AUTOIMMUNE DISORDERS
9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET
TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.9 BONE & MINERAL DISORDERS
9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.10 TOXICOLOGY
9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL
TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.12 THERAPEUTIC DRUG MONITORING
9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET
TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION)
9.13 METABOLIC DISORDERS
9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
FIGURE 37 GLOBAL INCIDENCE OF DIABETES
TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.14 GASTROENTEROLOGY
9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET
TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION)
9.15 NEUROLOGY
9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT
TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
9.16 RESPIRATORY
9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET
TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION)
9.17 OTHER APPLICATIONS
TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER
10.1 INTRODUCTION
TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET
TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT
TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.5 OTHER END USERS
TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
11.2.2 US
11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period
TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market
TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES
TABLE 70 CANADA: MACROECONOMIC INDICATORS
TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
11.3.2 GERMANY
11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market
TABLE 82 GERMANY: MACROECONOMIC INDICATORS
TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market
TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 UK
11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market
TABLE 93 UK: MACROECONOMIC INDICATORS
TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population and increasing support for research to drive market
TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Growing investments in clinical diagnostics research to drive market
TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 CHINA
11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period
TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD
11.5.2 LATIN AMERICA
11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market
TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 MIDDLE EAST & AFRICA
11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market
TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS
12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
12.4 MARKET SHARE ANALYSIS
TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION
FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
12.7 COMPETITIVE BENCHMARKING
TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPANY FOOTPRINT ANALYSIS
TABLE 164 OVERALL COMPANY FOOTPRINT
TABLE 165 COMPANY PRODUCT FOOTPRINT
TABLE 166 COMPANY REGIONAL FOOTPRINT
12.9 COMPETITIVE SCENARIO
12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023
12.9.2 KEY DEALS
TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023
12.9.3 OTHER KEY DEVELOPMENTS
TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.2 DANAHER CORPORATION
TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.3 SIEMENS HEALTHINEERS AG
TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
13.1.4 DIASORIN S.P.A.
TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.5 ABBOTT LABORATORIES
TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)
13.1.7 SYSMEX CORPORATION
TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
13.1.8 DIATRON
TABLE 177 DIATRON: COMPANY OVERVIEW
FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)
13.1.9 GETEIN BIOTECH, INC.
TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
13.1.10 WERFEN
TABLE 179 WERFEN: COMPANY OVERVIEW
13.1.11 QUIDELORTHO CORPORATION
TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MERCK KGAA
13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)
13.2.3 TRIVITRON HEALTHCARE
13.2.4 ABNOVA CORPORATION
13.2.5 ELABSCIENCE
13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.
13.2.7 AUTOBIO DIAGNOSTICS CO., LTD
13.2.8 JIANGSU ZECEN BIOTECH CO., LTD
13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
13.2.10 DAAN GENE CO., LTD.
13.2.11 DYNEX TECHNOLOGIES, INC.
13.2.12 ZYBIO INC.
13.2.13 WIENER LABORATORIOS SAIC
13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION
1.3.2 GEOGRAPHICAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 6 MARKET ESTIMATION FROM IVD MARKET
FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
FIGURE 9 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)
FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
4 PREMIUM INSIGHTS
4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW
FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022)
FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidences of chronic and infectious diseases globally
FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)
FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS)
5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years
5.2.1.3 Growth of biotechnology and biopharmaceutical industries
5.2.1.4 Rapid increase in geriatric population globally
FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.5 Shift toward personalized medicines and individualized treatment decisions
5.2.2 RESTRAINTS
5.2.2.1 High cost of chemiluminescence systems and reagents
5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference
5.2.3 OPPORTUNITIES
5.2.3.1 High growth prospects for players in emerging economies
5.2.3.2 Increasing number of collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems
5.2.4.2 Lack of skilled professionals and aging workforce
5.3 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
5.5.1 DEGREE OF COMPETITION
5.5.2 BARGAINING POWER OF SUPPLIERS
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 THREAT OF SUBSTITUTES
5.5.5 THREAT OF NEW ENTRANTS
5.6 KEY STAKEHOLDERS AND BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.6.2 BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS
TABLE 4 KEY BUYING CRITERIA, BY END USER
5.7 REGULATORY LANDSCAPE
5.7.1 US
TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES
5.7.2 CANADA
FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.7.3 EUROPE
TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES
5.7.4 JAPAN
FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.5 CHINA
TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.6 INDIA
FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.7.7 INDONESIA
TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.7.8 RUSSIA
TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.7.9 SAUDI ARABIA
TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.10 MEXICO
FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.11 BRAZIL
FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.7.12 SOUTH KOREA
TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.13 MIDDLE EAST
5.7.14 AFRICA
5.8 TECHNOLOGY ANALYSIS
TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.9 TRADE ANALYSIS
5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
5.10 ECOSYSTEM MAPPING
FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.10.1 ROLE IN ECOSYSTEM
5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024
5.13 PRICING ANALYSIS
5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)
TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD
TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE
TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE
TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 CHEMILUMINESCENCE ENZYME
7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION)
7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY
7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY
7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
8.2 BLOOD
8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
8.3 URINE
8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET
TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
8.4 SALIVA
8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET
TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SAMPLE TYPES
TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET
TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET
TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.4 ONCOLOGY
9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.5 CARDIOLOGY
9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET
TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
9.7 BLOOD SCREENING
9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET
TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.8 AUTOIMMUNE DISORDERS
9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET
TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.9 BONE & MINERAL DISORDERS
9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.10 TOXICOLOGY
9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL
TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
9.12 THERAPEUTIC DRUG MONITORING
9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET
TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION)
9.13 METABOLIC DISORDERS
9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
FIGURE 37 GLOBAL INCIDENCE OF DIABETES
TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.14 GASTROENTEROLOGY
9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET
TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION)
9.15 NEUROLOGY
9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT
TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
9.16 RESPIRATORY
9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET
TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION)
9.17 OTHER APPLICATIONS
TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER
10.1 INTRODUCTION
TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET
TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT
TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.5 OTHER END USERS
TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
11.2.2 US
11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period
TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market
TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES
TABLE 70 CANADA: MACROECONOMIC INDICATORS
TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
11.3.2 GERMANY
11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market
TABLE 82 GERMANY: MACROECONOMIC INDICATORS
TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market
TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 UK
11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market
TABLE 93 UK: MACROECONOMIC INDICATORS
TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population and increasing support for research to drive market
TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Growing investments in clinical diagnostics research to drive market
TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 CHINA
11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period
TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD
11.5.2 LATIN AMERICA
11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market
TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 MIDDLE EAST & AFRICA
11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market
TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS
12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
12.4 MARKET SHARE ANALYSIS
TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION
FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
12.7 COMPETITIVE BENCHMARKING
TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPANY FOOTPRINT ANALYSIS
TABLE 164 OVERALL COMPANY FOOTPRINT
TABLE 165 COMPANY PRODUCT FOOTPRINT
TABLE 166 COMPANY REGIONAL FOOTPRINT
12.9 COMPETITIVE SCENARIO
12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023
12.9.2 KEY DEALS
TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023
12.9.3 OTHER KEY DEVELOPMENTS
TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.2 DANAHER CORPORATION
TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.3 SIEMENS HEALTHINEERS AG
TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
13.1.4 DIASORIN S.P.A.
TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.5 ABBOTT LABORATORIES
TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)
13.1.7 SYSMEX CORPORATION
TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
13.1.8 DIATRON
TABLE 177 DIATRON: COMPANY OVERVIEW
FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)
13.1.9 GETEIN BIOTECH, INC.
TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
13.1.10 WERFEN
TABLE 179 WERFEN: COMPANY OVERVIEW
13.1.11 QUIDELORTHO CORPORATION
TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MERCK KGAA
13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)
13.2.3 TRIVITRON HEALTHCARE
13.2.4 ABNOVA CORPORATION
13.2.5 ELABSCIENCE
13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.
13.2.7 AUTOBIO DIAGNOSTICS CO., LTD
13.2.8 JIANGSU ZECEN BIOTECH CO., LTD
13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
13.2.10 DAAN GENE CO., LTD.
13.2.11 DYNEX TECHNOLOGIES, INC.
13.2.12 ZYBIO INC.
13.2.13 WIENER LABORATORIOS SAIC
13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
